Correlation of cell viability–based OOS threshold of 80% and outcomes by disease
| . | ALL, % (95% CI) . | NHL, % (95% CI) . | ||
|---|---|---|---|---|
| . | <80% viability (n = 33) . | ≥80% viability (n = 212) . | <80% viability (n = 43) . | ≥80% viability (n = 94) . |
| ORR (CR + PR) | — | — | 52% (36.4-68.0) | 65 (54.6-74.9) |
| BOR of CR | 94 (79.2-99.2) | 84 (78.3-88.8) | 31 (17.6-47.1) | 43 (33.2-54.2) |
| MRD− | 100 (81.5-100) | 99 (94.0-100) | — | — |
| DOR at 6 mo | 79 (54.6-90.9) | 79 (70.8-85.5) | 43 (18.8-64.5) | 59 (42.4-72.4) |
| EFS/PFS at 6 mo* | 80 (60.5-90.4) | 68 (60.3-74.0) | 29 (16.2-43.7) | 42 (31.2-52.3) |
| OS at 6 mo | 93 (74.6-98.2) | 88 (83.1-92.2) | 70 (53.5-82.1) | 71 (60.3-79.9) |
| CRS grade ≥3 | 21 (9.0-38.9) | 15 (10.2-20.1) | 2 (0.1-12.3) | 5 (1.7-12.0) |
| Neurotoxicity grade ≥3 | 15 (5.1-31.9) | 8 (4.7-12.5) | 5 (0.6-15.8) | 5 (1.7-12.0) |
| . | ALL, % (95% CI) . | NHL, % (95% CI) . | ||
|---|---|---|---|---|
| . | <80% viability (n = 33) . | ≥80% viability (n = 212) . | <80% viability (n = 43) . | ≥80% viability (n = 94) . |
| ORR (CR + PR) | — | — | 52% (36.4-68.0) | 65 (54.6-74.9) |
| BOR of CR | 94 (79.2-99.2) | 84 (78.3-88.8) | 31 (17.6-47.1) | 43 (33.2-54.2) |
| MRD− | 100 (81.5-100) | 99 (94.0-100) | — | — |
| DOR at 6 mo | 79 (54.6-90.9) | 79 (70.8-85.5) | 43 (18.8-64.5) | 59 (42.4-72.4) |
| EFS/PFS at 6 mo* | 80 (60.5-90.4) | 68 (60.3-74.0) | 29 (16.2-43.7) | 42 (31.2-52.3) |
| OS at 6 mo | 93 (74.6-98.2) | 88 (83.1-92.2) | 70 (53.5-82.1) | 71 (60.3-79.9) |
| CRS grade ≥3 | 21 (9.0-38.9) | 15 (10.2-20.1) | 2 (0.1-12.3) | 5 (1.7-12.0) |
| Neurotoxicity grade ≥3 | 15 (5.1-31.9) | 8 (4.7-12.5) | 5 (0.6-15.8) | 5 (1.7-12.0) |
EFS for ALL; PFS for NHL.